Philip Morris's smoke-free product portfolio (IQOS, ZYN) has reached 40% of revenue with ZYN shortage in the US validating demand and pricing power. IQOS recapture from Altria provides US accelerator. Smoke-free transition arc is well-established with credibility. Regulatory risk around oral nicotine products is the key swing factor. Dividend and FCF generation remain robust. Best-in-class capital allocation among consumer staples.
Signals scoped to US · Company-specific tagging coming soon.